down arrow

Minerva Neurosciences, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US6033802058
USD
3.74
0.49 (15.08%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.273.77

52 Week

1.1512.46
Valuation
Technical
Day's Volume

CASH

10.14 k

Shareholding (Mar 2025)

FII

0.49%

Held by 5 FIIs

DII

71.3%

Held by 28 DIIs

Promoter

0.00%

How big is Minerva Neurosciences, Inc.?

22-Jun-2025

As of Jun 18, Minerva Neurosciences, Inc. has a market capitalization of 12.87 million, with net sales of 0.00 million and a net profit of 6.26 million over the last four quarters. The balance sheet shows shareholder's funds of -25.69 million and total assets of 37.14 million.

As of Jun 18, Minerva Neurosciences, Inc. has a market capitalization of 12.87 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, while the net profit for the same period was 6.26 million.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of -25.69 million and total assets of 37.14 million.

Read More

What does Minerva Neurosciences, Inc. do?

22-Jun-2025

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system diseases, with a market cap of $12.87 million and a recent net profit of -$4 million.

Overview: <BR>Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing product candidates for central nervous system (CNS) diseases, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 12.87 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 2.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.46 <BR>Return on Equity: -21.46% <BR>Price to Book: -0.44<BR><BR>Contact Details: <BR>Address: 1601 Trapelo Rd Ste 286, WALTHAM MA: 02451-7337 <BR>Tel: ['1 617 6007373', '1 617 6007376'] <BR>Fax: 1 302 6365454 <BR>Website: http://minervaneurosciences.com/

Read More

Who are in the management team of Minerva Neurosciences, Inc.?

22-Jun-2025

As of March 2022, the management team of Minerva Neurosciences, Inc. includes Dr. Remy Luthringer (CEO and Executive Chairman), Mr. William Doyle (Lead Independent Director), and four Independent Directors: Mr. Hans Hasler, Ms. Jeryl Hilleman, Dr. David Kupfer, and Dr. Fouzia Laghrissi-Thode. They oversee the company's strategic direction and governance.

As of March 2022, the management team of Minerva Neurosciences, Inc. includes the following individuals:<BR><BR>- Dr. Remy Luthringer, who serves as the Chief Executive Officer and Executive Chairman of the Board of Directors.<BR>- Mr. William Doyle, who is the Lead Independent Director.<BR>- Mr. Hans Hasler, serving as an Independent Director.<BR>- Ms. Jeryl Hilleman, also an Independent Director.<BR>- Dr. David Kupfer, who is an Independent Director.<BR>- Dr. Fouzia Laghrissi-Thode, serving as an Independent Director.<BR><BR>This team is responsible for guiding the strategic direction and governance of the company.

Read More

Is Minerva Neurosciences, Inc. overvalued or undervalued?

25-Jun-2025

As of August 2, 2021, Minerva Neurosciences, Inc. is considered overvalued with a significant downgrade in investment appeal, reflected by a P/E ratio of 2.06 and a YTD decline of -20.33%, contrasting sharply with the S&P 500's gain of 2.44%.

As of 2 August 2021, Minerva Neurosciences, Inc. has moved from a valuation grade of very attractive to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently considered overvalued. Key ratios include a P/E ratio of 2.06, an EV to EBIT of -2.91, and a PEG ratio of 0.02, which suggest poor profitability and growth prospects.<BR><BR>In comparison to its peers, Veru, Inc. has a P/E of -2.30 and an EV to EBITDA of -1.71, while Outlook Therapeutics, Inc. has a P/E of -0.95 and an EV to EBITDA of -1.28, both indicating challenges in their respective valuations. The negative return of Minerva Neurosciences compared to the S&P 500, particularly a YTD decline of -20.33% versus a gain of 2.44% for the index, further reinforces the notion of overvaluation amidst its deteriorating financial health.

Read More

Is Minerva Neurosciences, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Minerva Neurosciences, Inc. shows a mildly bullish technical trend with mixed signals from various indicators, while significantly underperforming the S&P 500 with a 1-year return of -27.72% and a 3-year return of -77.46%.

As of 8 September 2025, the technical trend for Minerva Neurosciences, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating a positive momentum. The daily moving averages are also mildly bullish, suggesting some upward pressure. However, the Bollinger Bands show a mixed signal with a mildly bullish weekly stance and a bearish monthly stance. The KST is bullish on a weekly basis but mildly bullish monthly, while the Dow Theory indicates a mildly bearish weekly trend with no trend monthly. Overall, the technical stance is mildly bullish but lacks strong confirmation from several indicators.<BR><BR>In terms of performance, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a 1-year return of -27.72% versus the S&P 500's 17.14%, and a staggering 3-year return of -77.46% compared to the S&P 500's 70.41%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 15 Million ()

stock-summary
P/E

2.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.39

stock-summary
Return on Equity

-34.97%

stock-summary
Price to Book

-0.47

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
55.83%
0%
55.83%
6 Months
113.11%
0%
113.11%
1 Year
70.01%
0%
70.01%
2 Years
-48.41%
0%
-48.41%
3 Years
10.0%
0%
10.0%
4 Years
-49.52%
0%
-49.52%
5 Years
-81.95%
0%
-81.95%

Minerva Neurosciences, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Minerva Neurosciences, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Minerva Neurosciences, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating a positive momentum. The daily moving averages are also mildly bullish, suggesting some upward pressure. However, the Bollinger Bands show a mixed signal with a mildly bullish weekly stance and a bearish monthly stance. The KST is bullish on a weekly basis but mildly bullish monthly, while the Dow Theory indicates a mildly bearish weekly trend with no trend monthly. Overall, the technical stance is mildly bullish but lacks strong confirmation from several indicators. In terms of performance, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a 1-year return of -27.72% versus the S&P 500's 17.14%, and a staggering 3-year return of -77.46% compared to the S&P 500's ...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-14.89%
EBIT to Interest (avg)
-14.70
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.46
Sales to Capital Employed (avg)
0.91
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
37.89%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
2
Industry P/E
Price to Book Value
-0.44
EV to EBIT
-2.91
EV to EBITDA
-2.91
EV to Capital Employed
4.12
EV to Sales
NA
PEG Ratio
0.02
Dividend Yield
NA
ROCE (Latest)
-141.66%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 5 Schemes (28.21%)

Foreign Institutions

Held by 5 Foreign Institutions (0.49%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 59.76% vs -32.26% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.40",
          "val2": "-6.30",
          "chgp": "46.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "2.30",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.30",
          "val2": "-8.20",
          "chgp": "59.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 104.67% vs 6.54% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-21.80",
          "val2": "-23.10",
          "chgp": "5.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.60",
          "val2": "8.30",
          "chgp": "-44.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1.40",
          "val2": "-30.00",
          "chgp": "104.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-3.40
-6.30
46.03%
Interest
0.00
2.30
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.30
-8.20
59.76%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 59.76% vs -32.26% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-21.80
-23.10
5.63%
Interest
4.60
8.30
-44.58%
Exceptional Items
0.00
0.00
Consolidate Net Profit
1.40
-30.00
104.67%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 104.67% vs 6.54% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Minerva Neurosciences, Inc. stock-summary
stock-summary
Minerva Neurosciences, Inc.
Pharmaceuticals & Biotechnology
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease.
Company Coordinates stock-summary
Company Details
1601 Trapelo Rd Ste 286 , WALTHAM MA : 02451-7337
stock-summary
Tel: 1 617 60073731 617 6007376
stock-summary
http://minervaneurosciences.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."